MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates

分组1 - MARKER THERAPEUTICS reported a quarterly loss of $0.04 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.21, representing an earnings surprise of +80.49% [1] - The company posted revenues of $1.1 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 83.83%, although this is a decline from year-ago revenues of $2.25 million [2] - The stock has underperformed the market, losing about 8.7% since the beginning of the year compared to the S&P 500's decline of 1.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.22 on revenues of $0.6 million, and for the current fiscal year, it is -$1.86 on revenues of $2.3 million [7] - The Medical - Drugs industry, to which MARKER THERAPEUTICS belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]